Skip to content
Biodatica
Start free

Investigator

Raquel Hontecillas

BIOTHERAPEUTICS, INC. · funded by NIAID

Companies
2

Resolved onto their grants.

Grants
2

Federal awards on file.

Non-dilutive funding
$461k

Summed across those awards.

First award
Dec 1, 2024

Latest Aug 13, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R43

    Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD

    $314k

    Aug 13, 2025NIAIDBIOTHERAPEUTICS, INC.NIH RePORTER · 11181229 (opens the source filing in a new tab)

  2. R21

    Immunometabolic Mechanisms of Protection against Infection

    $147k

    Dec 1, 2024NIAIDNIMML INSTITUTE, INC.NIH RePORTER · 11238034 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources